Connect with us

Health

GLP-1s can help address LGBTQ healthcare barriers: experts

Queer people more subject to body dissatisfaction

Published

on

More and more people are turning to GLP-1s to lose weight. (Photo by CarolinaR/Bigstock)

Dana Piccoli tried everything to lose weight. 

She frequented the gym, went on and off diets and hired a personal trainer. When Piccoli decided to get on a GLP-1, it wasn’t a “short cut” to drop weight – it was a way for her to live her life comfortably.

“When I told someone I was on it, they were like, ‘I’m going to the gym because I want to do it the right way,’” said Piccoli, managing director of queer media collaborative News is Out. “Obviously that kind of stung because for me, this is the right way.”

GLP-1 drugs have caused quite a stir since becoming more integrated into mainstream medicine. The newness of some brands, like Ozempic, have led to stigmas and mistrust surrounding them. These stigmas disproportionately affect the LGBTQ+ community since queer people are more subject to body dissatisfaction and have more trouble finding accessible healthcare.

Through all the noise, however, experts say taking GLP-1s are safe with the right counseling, and LGBTQ+ people could largely benefit from them.

So, what’s all the ruckus about? Are GLP-1s an “easy way out” to lose weight? And how do they really impact the LGBTQ+ community?

How GLP-1s work

GLP-1s, or glucagon-like peptide-1, mimic the actions of a GLP-1 that is released by the gut after eating. It can help people with Type-2 diabetes by lowering blood sugar through the release of insulin, and can help those with obesity by slowing down digestion and, in turn, reducing one’s appetite.

Like any medication, there are some side effects to consider. Sangeeta Kashyap, assistant chief of clinical affairs at Weill Cornell Medicine, said symptoms like nausea, diarrhea, and vomiting can occur. However, Kashyap said these side effects are less severe than past GLP-1 brands – a reason that contributes to their newfound popularity – and can be better managed with proper guidance. 

Since the drug causes a loss of both fat and muscle loss, she said doctors should inform patients to do strength training to maintain any deteriorating muscle, and to eat high-protein diets, since fatty foods increase the risk of vomiting or nausea.

Getting on a GLP-1 isn’t just about shedding a few pounds. Kashyap said it’s a commitment to your health and body, which is why talking with a doctor and understanding the risks are crucial.

“We give patients appropriate guidelines,” Kashyap said. “We do blood tests, we monitor things, and give a lot of counseling to these patients. I don’t think you could just give the medicine out like candy.”

Piccoli, who started her GLP-1 journey with her wife, said the medication helped turn off “food noise.”

“Your motivation for things, your reward system with food is kind of disabled,” Piccoli said. “That really helped me understand my relationship with food.”

Turning down food noise

Losing weight isn’t as easy as getting on a GLP-1 and eating less. Piccoli said turning off the food noise in her brain led to a complete lifestyle shift.

“I had to completely change everything about the way I eat, everything about the way I approach food,” she said about her experience taking Mounjaro. “This has been one of the hardest things I’ve ever done.”

Kashyap said the lifestyle change that comes with taking a GLP-1 is why it’s important to consult a doctor first to understand how it could affect you not just physically, but also emotionally.

Kashyap said she sees higher rates of mental health disorders in transgender women, a community that already faces more barriers in finding accessible healthcare. 

This could lead to someone getting on the drug for the wrong reasons, Kashyap said. She noted that those with eating disorders or body dysmorphia could face more severe side effects. Body dysmorphia and body image concerns are already an issue for the LGBTQ+ community, Kashyap said, so prescribing GLP-1s needs to be handled with care.

One way to ethically prescribe a GLP-1 to a patient would be to conduct a mental health screening, according to Kashyap. Mental health screenings aren’t required to get on a GLP-1, but Kashyap said they would be beneficial to patients who may be prone to negative effects by taking the drug. 

Although some people may see more severe side effects, Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women’s Hospital, said GLP-1s are a completely safe and rigorously tested drug. 

If a person faces negative side effects from taking a GLP-1, it’s more about how their body or brain is reacting to it than the drug itself being unsafe.

“Any kind of weight loss is going to affect your mood, either positively or negatively,” Apovian said.

With the queer community already facing increased barriers to healthcare, there’s another issue to consider: GLP-1s aren’t cheap.

Depending on where you get it from and whether or not insurance covers it, you could pay hundreds or even thousands of dollars for a limited supply.

Piccoli said she paid out of pocket and had to make sacrifices for her and her wife to both get on a GLP-1. 

“I didn’t renew my car lease,” Piccoli said. “We decided to go down to one car so that we had some extra income monthly to be able to pay for it.”

On the other hand, Matt, who requested to be identified only by his first name due to the sensitivity of the topic, said he was shocked at how easy it was to get the cost of his GLP-1 covered by insurance. He had been warned by his doctor about the difficulty of getting it covered, and expected an “uphill battle.”

“[My doctor] wrote out the prescription for me, and on my way home, I got a text message from the drugstore saying it was ready to go,” said Matt, who’s lost 48 pounds on Ozempic since June 2024. 

Matt said experiences like his, although not the standard, are why it’s important to talk with your doctor about getting on a GLP-1 and see for yourself rather than taking advice from social media stigmas. 

Kashyap said the drug is also becoming more accessible through websites like Lilly, which provide vials for about $300-500. While that isn’t pocket change, it’s significantly cheaper than retail pharmacies.

You may have to make sacrifices like Piccoli did, but getting access to modern GLP-1s for weight loss isn’t only for the Hollywood elites like it seemed to be a few years ago.

Through all the social stigmas and uncertainty, Kashyap and Apovian agreed that GLP-1s are a major benefit for the queer community.

Trans women have increased rates of obesity, Type-2 diabetes and metabolic syndrome, according to Kashyap. Estrogen treatments increase fat mass and insulin resistance, leading to higher obesity rates in trans women. Kashyap said GLP-1s could be helpful in mitigating those effects.

GLP-1s also reduce alcohol cravings, so Kashyap noted that anyone struggling with alcoholism may see improvements with that condition upon getting on the drug. 

Getting on a GLP-1 isn’t the walk in the park some may make you believe it is – it’s a lifestyle change and health commitment.

But it’s also a change that can provide good and healthy results if you seek the appropriate guidance from a professional.

While social stigmas in the queer community may lead to misinformation on who should use it and what it should be used for, GLP-1s are safe and can be a much-needed relief for a community facing significant healthcare obstacles.

Advertisement
FUND LGBTQ JOURNALISM
SIGN UP FOR E-BLAST

Health

United States Conference on HIV/AIDS grapples with federal budget cuts

Annual gathering is largest of its kind in the country

Published

on

Bishop Antonio José Gallardo Lucena addresses the United States Conference on HIV/AIDS in Anaheim, Calif., on Sep 17, 2026. (Photo by Caleb Kaufman for the Los Angeles Blade)

Advocates, public health experts, and healthcare providers gathered for the United States Conference on HIV/AIDS on Sept. 17 in Anaheim, Calif.

The conference is the largest of its kind in the nation and came amid a wave of new challenges for HIV research and treatment. Since the beginning of the second Trump-Vance administration, federal spending cuts have targeted HIV/AIDS programs, including the gutting of the U.S. Agency for International Development and proposed cuts to PEPFAR, which supports HIV testing and treatment globally, in 2025. 

Last year, Congress maintained funding for HIV programs after proposed cuts faced opposition from advocacy groups and bipartisan criticism. Yet, this year Congress has proposed similar cuts to many of the same programs, which would cut nearly one billion dollars in HIV funding. The majority of the cuts would impact HIV prevention and outreach, which includes ending nearly all Centers for Disease Control and Prevention HIV prevention activities. 

“If we continue down this path,” said Jeremiah Johnson, the executive director of PrEP4ALL, an advocacy group that supports expanding access to HIV prevention. “We’re going to see more people falling off treatment. We’re going to see more wait lists. That’s going to lead to more people dying from AIDS-related complications.”

Cuts and challenges

The funding cuts loomed over the conference and inspired protest from activists. 

On the first day of USCHA, activists with Save HIV Funding organized a mock funeral outside the convention center. Advocates living with HIV wrote eulogies for themselves, meant to show the consequences of diminished access to treatment. Then activists marched through the conference carrying fake coffins. 

Johnson, who helped organize the protest, said that “the Trump administration has eviscerated global aid … and the fears that many of us are just talking about hypothetically for ourselves at the moment are already happening [internationally]. And so we wanted to place that front and center at this conference.”

The attacks on funding for HIV research and outreach come at a complicated time for the movement to end the AIDS epidemic. While options for prevention and treatment have never been more accessible, such as PrEP and antiretroviral therapy, there have been some concerning upticks in infections, particularly among communities of color.

Southern states account for the majority of new HIV infections in the country, despite making up only 38 percent of the population. And these infections impact disproportionately Black and Latino communities. According to the CDC, even as overall HIV infections decreased from 2018 to 2022, diagnoses of HIV among Latinos grew by 17 percent, with a majority of this increase happening in the South. 

Stigma is still the biggest barrier for people seeking out HIV treatment, said Guillermo Chacón, president of the Latino Commission on AIDS. 

“The progress that we [made] in the past two years has been demolished,” he said. 

Chacón blames the federal government for stigmatizing HIV treatment by using harmful rhetoric about queer people. 

“The level of homophobia and transphobia right now is even higher because it has been used as a political message to create fear and division in our country,” he said. 

Chacón believes that research and outreach must be done to reverse the rising HIV infections among Latinos. However, this is exactly the type of research that the Trump-Vance administration is targeting most intensely. Research into “health disparities” — why some health problems impact certain communities more than others — has been heavily criticized by the White House, along with other research that it considers “woke” and claims is not supported by science. 

Impact felt at conference

The opening plenary for the conference addressed some of the funding challenges the movement was facing but tried to shift the focus to the victories the movement has seen over the years. Speakers highlighted historic successful activist campaigns like ACT UP, and recent improvements in medical care and access to treatment. 

Randevyn Pierre, head of U.S. external affairs at ViiV Healthcare, the sponsor of the plenary, took the stage to celebrate the success of the U = U campaign (undetectable viral load =
untransmittable HIV virus), and ViiV’s investment of $33 million in HIV community organizations across the U.S. This comes as the Trump-Vance administration has made moves to end direct funding of community-based organizations, opting to give the funding to state healthcare agencies. 

The speakers at the conference discussed reducing stigma for those living with HIV and the joy of living authentically. They also emphasized the diverse groups of people that are impacted by HIV and how they can come together to fight for a cure. Longtime AIDS activist Rae Lewis Thorton exclaimed, “When they tell me there’s a cure to HIV, I’m gonna take off my 4-inch heels and put on gold slippers,” to applause from the audience. 

The opening plenary also featured song and dance from a variety of artists, many of whom spoke about how HIV has impacted their own lives and how advocacy has uplifted their spirits. However, the joyous atmosphere at the conference would not last. 

On the final day of USCHA, Geri Donenberg, the associate director of AIDS research at the National Institutes of Health, took the stage to address the conference. 

As she spoke, phones began to buzz around the room with breaking news: the Trump-Vance administration was drafting an executive order to create an external board to oversee NIH grants and screen them for political content. NMAC CEO Harold Philips took the stage after Donenberg to address the crowd. “It’s up to us,” Philips said, “to hold NIH accountable.” He added that HIV advocates “have supporters inside NIH who are struggling and working to do the right thing. We have to have their back.” 

Chants of “stand up, fight back, fight AIDS” erupted from the crowd as Philips spoke. “We do have to fight back. We do have to continue to fight,” Philips replied. 

Caleb Kaufman is a California Local News Fellow placed with the Los Angeles Blade. The California Local News Fellowship is a state-funded initiative to support and strengthen local news reporting. Learn more about it at fellowships.journalism.berkeley.edu/cafellows.

Continue Reading

Health

AIDS Healthcare Foundation announces 3 million people globally in its care

Los Angeles-based group lauded ‘historic milestone’

Published

on

An AIDS Healthcare Foundation float in the Lima Pride parade in Lima, Peru, on July 1, 2023. (Photo courtesy of Jacob Kessler)

The AIDS Healthcare Foundation, a Los Angeles-based nonprofit group founded in 1987 that has become the world’s largest HIV/AIDS organization, has announced it has three million people in care around the world.

In a statement released on May 26, the organization, known worldwide as AHF, said the latest accomplishment reflects its global commitment to HIV prevention, care, and treatment. It says the accomplishment comes at a time when AHF marks the 25th anniversary of its first global programs launched in South Africa and Uganda in early 2001.

The statement says the three million people in care milestone also comes while the group approaches the 40th anniversary of its founding in 1987.

“Today, AHF provides lifesaving services in 50 countries across Africa, the Americas, Asia, and Europe, supporting millions of people living with HIV through a network of 1,056 global clinics, 79 healthcare centers in the U.S., 67 pharmacies, 96 wellness centers, 26 Out of the Closet thrift stores, outreach programs, and community partnerships,” the statement says.   

“This accomplishment is far more than a number — it represents 3 million individuals whose lives have been touched by compassion, commitment, and the belief that healthcare is a human right,” Condessa M. Curley, the AHF board chair, said in a statement. “We extend our deepest gratitude to every member of the AHF team whose dedication made this milestone possible,” Curley said.

The AHF website notes the organization was founded in 1987 in Los Angeles as a network of hospices committed to “fighting for the living and caring for the dying” at a time when there was no effective treatment for HIV/AIDS. A statement on the website says since that time AHF has greatly expanded, converting its hospices into healthcare centers “and building a new paradigm for HIV care both in the United States and around the world.”  

The statement adds, “Under the leadership of president and co-founder Michael Weinstein, AHF has grown from a group of friends dedicated to creating dignified hospice care to the largest AIDS organization in the world.” It says Weinstein “has been at the forefront of creating cutting-edge healthcare and advocacy programs and continues to drive the organization forward with the aim of saving more lives around the world.”

The statement announcing the milestone has also come at a time when more than 40 million people worldwide are living with HIV, “while hundreds of thousands continue to die annually from AIDS-related illnesses despite the availability of effective treatment.”

It says AHF’s response has included an expansion of its prevention and public health programs worldwide. In 2025 alone, according to the statement, AHF and its affiliated programs provided nearly five million free HIV tests globally and distributed more than 54 million free condoms, “underscoring the organization’s continued emphasis on both prevention and treatment.”

In D.C. AHF operates health care centers at 1701 K St., N.W., Ste. 400 [202-293-8680], 650 Pennsylvania Ave., S.E., Ste. 310 [202-350-5000], and 1647 Benning Road, N.E., Ste. 300 [202-350-5000]. 

Continue Reading

Cannabis Culture

LGBTQ people, weed, and mental health: what you need to know

Community uses marijuana at much higher rates than general population

Published

on

(Photo courtesy of NORML)

Uncloseted Media published this story on May 7.

By SPENCER MACNAUGHTON | In 2025, the global cannabis market size was valued at nearly $103 billion. By 2034, that number is expected to explode by roughly 1,400 percent to more than $1.43 trillion.

In short, as an increasing number of countries legalize marijuana use, everyone is starting to consume a lot more weed. And LGBTQ people tend to use cannabis at much higher rates than the general population. One study found that 55 percent of lesbian and 45 percent of gay young adults use marijuana, compared to about 33 percent and 37 percent, respectively, of their straight counterparts.

As LGBTQ people face a mental health crisis, the mainstream stereotypes that depict weed as an antidote for anxiety, panic and depression aren’t painting the full picture. And that could be exacerbating the mental health struggles so many queer people, and especially youth, face.

Here’s what the research demonstrates about marijuana and its effects on mental health:

  • Multiple studies suggest a link between marijuana use and an increased risk of mental health disorders, including schizophrenia, depression and anxiety in individuals who are genetically predisposed.
  • One study found that daily marijuana use, especially among younger people, makes some individuals seven times more likely to develop psychosis.

The increase in higher-potency strains of marijuana could pose unknown risks. In 1995, the average content of Tetrahydrocannabinol (THC) in confiscated marijuana was less than 4 percent. In 2022, it was more than 16 percent. Researchers don’t know the full extent of the impact that these higher concentrations can have on mental health and especially on younger people whose brains are still developing.

  • A systematic review of studies published between 2013 and 2025 found damning results for the mental health of young cannabis users:

They were 51 percent more likely to experience depression, 58 percent more likely to experience anxiety, between 50 and 65 percent more likely to experience suicidal ideation and 80 to 87 percent more likely to have attempted suicide.

  • While the above stats paint a grim picture, there is also some research that suggests benefits of cannabis use:
    • A 2025 systematic review found that “medicinal” weed showed some efficacy in relieving withdrawal symptoms of opioid use disorder. THC use has been associated with improvement of post-traumatic stress disorder symptoms, bipolar symptoms and sleep quality.
    • Other studies found that THC administered in a controlled setting was associated with a decrease of symptoms and adverse effects for a range of mental health disorders, including schizophrenia, psychotic symptoms, and anorexia nervosa.

Beyond what we pulled from academia, there is an astounding lack of information about the interplay between weed and mental health. As we dive deeper into Mental Health Awareness Month, I hope advocacy organizations, influencers and news outlets ramp up their coverage of this important topic that affects the countless LGBTQ weed smokers, many of whom are already struggling.

Continue Reading

Popular